

GOG-0275 NCTN/NCORP DATA ARCHIVE

Data as of: October 9, 2018

Notes

- 1 An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
- 2 doi: 10.1016/j.ygyno.2020.05.013
- 3 PMID: 32460997
- 4 Clinical trial information: NCT01535053.
- 5 Dataset ID: NCT01535053-D1.
- 6 Unless otherwise specified, blank values indicate missing data.
- 7 Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Var 1	Type	Label												
rx	N	Regimen												
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Actinomycin-D</td> </tr> <tr> <td>2</td> <td>Methotrexate</td> </tr> </tbody> </table>	Code	Definition	1	Actinomycin-D	2	Methotrexate						
Code	Definition													
1	Actinomycin-D													
2	Methotrexate													
Var 2	Type	Label												
country	C	country												
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>CA</td> <td>Canada</td> </tr> <tr> <td>JP</td> <td>Japan</td> </tr> <tr> <td>KR</td> <td>Korea</td> </tr> <tr> <td>UK</td> <td>United Kingdom</td> </tr> <tr> <td>US</td> <td>USA</td> </tr> </tbody> </table>	Code	Definition	CA	Canada	JP	Japan	KR	Korea	UK	United Kingdom	US	USA
Code	Definition													
CA	Canada													
JP	Japan													
KR	Korea													
UK	United Kingdom													
US	USA													

Var 3	Type	Label
race	C	Race

Code	Definition
-------------	-------------------

A	Asian
B	Black/African American
W	White

Var 4	Type	Label
ethnicity	N	Ethnicity

Code	Definition
-------------	-------------------

1	Hispanic or Latino
2	Non-Hispanic

Var 5	Type	Label
survstat	N	Survival Status

Code	Definition
-------------	-------------------

1	Alive
---	-------

Var 6	Type	Label
survtime	N	Overall Survival Time (Months)

Var 7	Type	Label
pfistat	N	Disease Recurred after Complete Response

Code	Definition
-------------	-------------------

1	Not recurred
2	Recurred

Var 8	Type	Label
whoscore	N	WHO Score

Code	Definition
-------------	-------------------

	Missing
--	---------

0	0
---	---

1	1
---	---

2	2
---	---

3	3
---	---

4	4
---	---

5	5
---	---

Var 9	Type	Label
Strat_route	C	MTX Regimen strata

Code	Definition
-------------	-------------------

IM	IM
----	----

IV	IV
----	----

Var 10	Type	Label
ptstat	N	Patient Status for Analysis (3 ineligible patients were not included in the analysis)

Code	Definition
-------------	-------------------

1	Ineligible
---	------------

3	Withdrew Consent for Follow-up
---	--------------------------------

4	Eligible and Treated
---	----------------------

Var 11	Type	Label
ctnew	C	Molar Class

Code	Definition
-------------	-------------------

	Missing
--	---------

C	Complete mole
---	---------------

CH	Choriocarcinoma
----	-----------------

P	Partial Mole
---	--------------

Var 12	Type	Label
agen	N	Age (years)

Var 13	Type	Label
bhcg	N	Registration Beta hCG (mIU/mL)

Code	Definition
2	10.1-100.0
3	100.1-1500.0
4	1500.1-5000.0
5	5000.1-10000.0
6	10000.1-100000.0
7	100000.1-1000000.0

Var 14	Type	Label
besthcgresp	C	Best hCG Response

Code	Definition
	Missing
C	Complete Response
N	Treatment Failure
N6	Treatment Failure not documented

Var 15	Type	Label
drug_arm	C	Regimen by Agent

Code	Definition
METHOTREXATE	METHOTREXATE
PULSE ACTINOMYCIN-D	PULSE ACTINOMYCIN-D

Var 16	Type	Label
ncrs	N	Number of Cycles

Var 17	Type	Label
upi	C	Universal Patient ID

Var 18	Type	Label
EY	N	Eye Disorders (Max Observed Grade)

Code	Definition
0	0
1	1
2	2

Var 19	Type	Label
GA	N	Gastrointestinal Disorders (Max Observed Grade)

Code	Definition
0	0
1	1
2	2
3	3

Var 20	Type	Label
GN	N	General Disorder and Administration Site Conditions (Max Observed Grade)

Code	Definition
0	0
1	1
2	2
3	3

Var 21	Type	Label										
IN	N	Infections/infestations (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 22	Type	Label								
MU	N	Musculoskeletal/Connective Tissue Disorders (Max Observed Grade)								
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2
Code	Definition									
0	0									
1	1									
2	2									

Var 23	Type	Label										
NV	N	Nervous System Disorders (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 24	Type	Label										
PS	N	Psychiatric Disorders (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 25	Type	Label								
RS	N	Reproductive/Breast Disorders (Max Observed Grade)								
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2
Code	Definition									
0	0									
1	1									
2	2									

Var 26	Type	Label								
RT	N	Respiratory/Thoracic/Mediastinal Disorders (Max Observed Grade)								
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2
Code	Definition									
0	0									
1	1									
2	2									

Var 27	Type	Label										
SK	N	Skin/Subcutaneous Tissue Disorders (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 28	Type	Label										
BL	N	Blood and Lymphatic System Disorders (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 29	Type	Label
IV	N	Investigations (Max Observed Grade)

Code	Definition
-------------	-------------------

0	0
---	---

1	1
---	---

2	2
---	---

3	3
---	---

Var 30	Type	Label
IM	N	Immune System Disorders (Max Observed Grade)

Code	Definition
-------------	-------------------

0	0
---	---

1	1
---	---

Var 31	Type	Label
EA	N	Ear and Labyrinth Disorders (Max Observed Grade)

Code	Definition
-------------	-------------------

0	0
---	---

1	1
---	---

Var 32	Type	Label
VA	N	Vascular Disorders (Max Observed Grade)

Code	Definition
-------------	-------------------

0	0
---	---

1	1
---	---

2	2
---	---

Var 33	Type	Label								
CD	N	Cardiac Disorders (Max Observed Grade)								
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2
Code	Definition									
0	0									
1	1									
2	2									

Var 34	Type	Label										
ME	N	Metabolism/Nutrition Disorders (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											

Var 35	Type	Label						
IP	N	Injury/Poisoning/Procedural Complications (Max Observed Grade)						
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1
Code	Definition							
0	0							
1	1							

Var 36	Type	Label						
RE	N	Renal/Urinary Disorders (Max Observed Grade)						
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1
Code	Definition							
0	0							
1	1							

Var 37	Type	Label										
MO	N	Mucositis Oral (Max Observed Grade)										
		<table border="1"> <thead> <tr> <th>Code</th> <th>Definition</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> </tr> <tr> <td>1</td> <td>1</td> </tr> <tr> <td>2</td> <td>2</td> </tr> <tr> <td>3</td> <td>3</td> </tr> </tbody> </table>	Code	Definition	0	0	1	1	2	2	3	3
Code	Definition											
0	0											
1	1											
2	2											
3	3											